|drug1178||Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days Wiki||1.00|
|drug2932||Placebo 250 cc 24 hours continuous infusion for 15 days Wiki||1.00|
|D000075902||Clinical Deterioration NIH||0.71|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression. In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. Only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.
Description: Serious adverse events during the study period include transfusion reaction (fever, rash), transfusion related acute lung injury (TRAU) , transfusion associated circulatory overload (TACO) , transfusion related infectionMeasure: Serious adverse events in convalescent plasma treated patients Time: From baseline (enrolment) to 24 hours follow-up
Description: Change in SARS-CoV2 quantitative in nasopharyngeal swabMeasure: Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Description: Transfer to ICUMeasure: Transfer to ICU Time: at Baseline (admission to Covid-ward) until day 28
Description: in-hospital deathMeasure: in-hospital death Time: at Baseline (admission to Covid-ward) until day 28
Description: Change in SARS-CoV2 quantitative in plasmaMeasure: Virologic clearance in plasma of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Description: Duration of hospitalisationMeasure: Time to discharge from hospital after enrolment Time: at Baseline (admission to Covid-ward) until discharge (approx. 28 days)
Description: Rise of SARS-CoV-2 antibody titers (on day 1, 7, 14 and 28)Measure: Humoral immune response Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports